Navigation Links
Personalized medicine eliminates need for drug in 2 children
Date:1/31/2013

This press release is available in French.

Using genome-wide analysis, investigators at the Sainte-Justine University Hospital Research Center and the University of Montreal have potentially eliminated a lifetime drug prescription that two children with a previously unknown type of adrenal insufficiency had been receiving for 14 years. Over a lifespan, the adjustment in treatment represents an approximate saving of $10,000 in drug and test costs per patient. Moreover, the less invasive treatment regime can potentially reduce the lifetime risk of hypertension in the patients. "This is a real case of personalized medicine made possible today through the use of novel techniques in genomics," stated Dr. Mark Samuels, lead author of a paper published on the subject in January 2013 in the Journal of Clinical Endocrinology and Metabolism. Dr. Johnny Deladoy was the senior author of the article.

Fourteen years ago both children were diagnosed with adrenal insufficiency, a condition that occurs when the adrenal glands do not secrete enough hormones to control sugar and mineral levels in the blood. After having sequenced the part of the genome that codes for genes in one patient, the investigators identified mutations in POMC, the gene behind the disorder. They then showed that the disorder in the second patient was also caused by a similar mutation in the gene POMC. Identifying the causal gene allowed them to conclude that the only thing missing in the patients was the production of cortisol, the hormone that regulates blood sugar. They thus advised the patients to continue cortisol treatment, but that fludrocortisone treatment was unlikely to be necessary. So far, fludrocortisone has been stopped in one patient without any adverse effects, while the condition of the second patient is still being evaluated.

In addition to reducing the risks of hy
'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Report from the front lines of personalized reproductive medicine revolution
2. BodyMedia & FitOrbit Up the Ante in Personalized Weight Loss
3. Study advances use of stem cells in personalized medicine
4. Scanning innovation can improve personalized medicine
5. Privately owned genetic databases may hinder diagnosis and bar the way to the arrival of personalized medicine
6. How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment
7. Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics
8. Chromosomal translocations point the way toward personalized cancer care
9. Advances in personalized medicine for lung cancer
10. Beers bitter compounds could help brew new medicines
11. Microdosing: Updating its role in developing new medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... Nanyang Technological University (NTU) and Imperial College London today ... medical school. The initiative was previously announced by Prime ... 2010, in August. Presently, the working name for the ... (ICNMS). To start in 2013, ICNMS will ...
... & Science University Doernbecher Children,s Hospital will lead the ... assess the safety and preliminary effectiveness of purified human ... infantile or late-infantile neuronal ceroid lipofuscinosis (NCL), a rare ... children. The Phase Ib trial, sponsored by StemCells, ...
... parenting skills. Most species leave their freshly hatched fry ... Buckley from the University of Plymouth, UK, explains that ... parents secrete over their bodies until they are big ... is very unusual, says Buckley. Intrigued by the fish,s ...
Cached Biology News:Imperial and NTU's new medical school aspires to be global health care role model 2Imperial and NTU's new medical school aspires to be global health care role model 3Imperial and NTU's new medical school aspires to be global health care role model 4OHSU Doernbecher Children's Hospital conducts second phase of landmark Batten study 2Discus fish parent young like mammalian mothers 2
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company ... in a Phase I study of BHV-0223, a ... application (IND) regarding BHV-0223 and recently obtained clearance ... to proceed with human testing. Portage holds 54% ...
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... will form the basis of a DNA diagnostic test to identify women ... into ... deCODEme(TM), REYKJAVIK, Iceland, April 27 ... of two common,single-letter variants (SNPs) on chromosome 5 of the human genome ...
... SAN DIEGO, April 25 Amylin Pharmaceuticals,Inc. (Nasdaq: ... Global,Healthcare Unplugged Conference in Key Biscayne, FL on Thursday, ... PT. Daniel M. Bradbury, President and,Chief Executive Officer of ... live presentation and breakout session will be webcast, and ...
... LINTHICUM, Md., April 25 Dialysis Corporation,of America (Nasdaq: ... its first,quarter 2008 financial results on May 7, 2008, ... host a conference call in conjunction with,its first quarter ... 10:00 AM EDT., Those interested in participating in ...
Cached Biology Technology:deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 3deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 4deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 5Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date 2
... DNase I Amplification ... double-stranded DNA to oligodeoxyribonucleotides. ... >10000 units/mg. DNAse I ... purified and tested for ...
... for the determination of digitonin and digoxin. Physical ... Na 4 and 0.06% NaCl Preparation Note: ... Biochem. Biophys. Res. Commun., 19, 755 (1965). ... of inorganic phosphorus from ATP per min at ...
... ds Qualified is a special preparation of bovine ... double stranded cleavage of DNA molecules. In the ... enzyme makes double strand breaks at random sites ... fragments can be controlled by the enzyme concentration ...
... type 14 3C protease from human rhinovirus ... the Novagen brand line of restriction grade ... purified recombinant 6XHis-fusion protein, which recognizes the ... LeuGluValLeuPheGln/GlyPro. The small, 22 KDa size of ...
Biology Products: